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Most immature T precursor cells that have emigrated to the thymus express neither CD4 nor CD8 co-receptors and are classified as CD4 À
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À double-negative (DN) thymocytes. At this DN stage, cells that succeed to express a functional TCRb chain as a consequence of VDJ rearrangement at the TCRb locus are selected for further maturation. These cells start to express both CD4 and CD8 co-receptors concomitant with VJ rearrangement of the TCRa gene and comprise the large subset of CD4 þ CD8 þ double-positive (DP) thymocytes. The DP thymocytes are then subjected to selection based on their aptitude to interact with MHC molecules (von Boehmer et al., 1993; Sebzda et al., 1999) . Only DP thymocytes with TCRs of a proper affinity for self-peptides presented on MHC undergo further differentiation, through a process known as positive selection. While DP thymocytes selected by interacting with MHC class I extinguish CD4 expression and become CD4 À
þ SP thymocytes (CD8 þ SP cells) with cytotoxic function, those selected via MHC class II extinguish CD8 expression and become CD4 þ CD8 À SP thymocytes (CD4 þ SP cells) with helper functions. Therefore, a molecular understanding of how DP thymocytes extinguish the expression of either coreceptor will shed light on how fates of DP thymocytes, differentiating into either helper or cytotoxic lineages, are decided. Since the lineage-specific expression of coreceptors is regulated at the transcriptional level, many studies have focused on the identification of cisregulatory regions in the CD4 or CD8 loci (Ellmeier et al., 1999; Kioussis & Ellmeier, 2002; Taniuchi et al., 2004) .
Several cis-regulatory elements including the promoter, enhancer and silencer, are involved in CD4 gene regulation ( Figure 1a) . Use of transgenic reporter mice identified a 434 bp fragment from intron 1 as the CD4 silencer capable of repressing reporter gene expression in both CD4 À CD8 À DN thymocytes and CD8 þ SP thymocytes, while a proximal enhancer activated reporter gene expression in all subsets of thymocytes (Sawada et al., 1994; Siu et al., 1994; Donda et al., 1996) . Furthermore, gene-targeting studies demonstrated that CD4 is de-repressed at both DN and CD8 þ SP stages of thymocyte development upon deletion of the CD4 silencer from the CD4 locus (Leung et al., 2001; Zou et al., 2001) . These genetic studies confirmed that the CD4 silencer is necessary for lineagespecific expression of CD4, and indicated that the 434 bp region is sufficient for silencer activity. Thus, a common cis-regulatory element, the CD4 silencer, is essential for repression of CD4 at distinct developmental stages. However, mechanisms of CD4 repression at the DN and CD8 þ SP stages are thought to be fundamentally different, although they are likely to share some general features.
Active repression versus epigenetic gene silencing of CD4 at distinct developmental stages Through a combination of transient transfections and transgenic mouse reporter assays, three essential sites (site1, site 2 and site 3) were identified within the 100 bp core of the CD4 silencer (Figure 1a ) (Taniuchi et al., 2002b) . Targeted mutations into any of these sites resulted in compromised function of the silencer, manifested by partial de-repression of CD4 in both immature DN thymocytes and in mature CD8-lineage T cells. However, the patterns of CD4 de-repression were different at these two stages.
In mice harboring mutations at a single functional site within the CD4 silencer, de-repression of CD4 was observed in only a proportion of mature CD8-lineage cells, while CD4 was silenced in another subset of cells that contained the same mutations (Taniuchi et al., 2002b) . Thus, CD8 þ cytotoxic T cells exhibited 'variegated' CD4 de-repression upon compromised function of the CD4 silencer. In contrast, variegated CD4 derepression was not observed in DN thymocytes bearing the same mutations ( Figure 1a) . In DN thymocytes, CD4 was 'uniformly' de-repressed (Taniuchi et al., 2002b) . The phenomenon in which cells of same lineage, containing identical genomic information, manifest distinct gene expression patterns is often observed in transgenic mice or at sites adjacent to chromosomal translocations, and is known as position effect variegation (PEV). Specific chromatin structures, such as heterochromatin, are thought to be involved in PEV (Wakimoto, 1998; Festenstein & Kioussis, 2000) .
These results suggested that, in DN thymocytes, CD4 is actively repressed by a combination of transcription factors. Thus, loss of binding of any one of these factors would result in partial, but 'uniform', de-repression of CD4. In contrast, in cells committed to the CD8 lineage, loss of binding to any single site in the silencer would reduce the probability of recruiting a complex that modifies chromatin during a critical developmental window. Studies on the role of Runx family members in CD4 repression at the two stages of development are consistent with this conclusion (see below).
The repression in DN thymocytes must be reversible, since thymocytes turn on CD4 expression immediately after transition to the DP stage. In contrast, CD4 remains stably silenced in mature cytotoxic T cells. Importantly, once cells succeed in silencing CD4 despite the absence of a single binding site within the silencer, the silenced status is maintained stably through multiple mitoses (Taniuchi et al., 2002b) . This is a key feature indicating that the silencer functions epigenetically in CD8-lineage T cells. The silenced state of gene expression would be stably maintained by inheritance of specific chromatin structures.
Use of mutant mice in which the CD4 silencer could be deleted at different stages of development provided persuasive evidence that the CD4 silencer is not required for the maintenance of CD4 silencing in mature CD8-lineage cells. Deletion of the CD4 silencer flanked by recombinase recognition sites (loxP) in purified mature CD4 À
þ SP cells, by using a Cre-encoding retrovirus, did not result in CD4 de-repression, even after several mitoses (Zou et al., 2001) . This result suggested that a chromatin-modifying complex, recruited by silencer-binding factors, marks the CD4 locus with an epigenetic tag, which is then inherited in the absence of the CD4 silencer (Figure 1b) .
Interestingly, a deletion of the silencer in mature thymocytes newly committed to the CD8 lineage, in which CD4 silencing was already observed, led to derepression of CD4 in peripheral mature CD8 þ T cells (Zou et al., 2001) . Presumably, a discrete time window for factors binding to the silencer is necessary to complete modifications of the chromatin. In yeast, a model of stepwise chromatin modification was proposed for heterochromatinization at the silent mating-type loci. This process is initiated by deacetylation of histone by a histone deacetylase (HDAC), followed by methylation of lysine 9 in histone H3 by histone methyltransferase (HMT), and then recruitment of the yeast homologue of heterochromatin protein-1 (HP-1), one of the major heterochromatin structural components (Nakayama et al., 2001) . HP-1 was found to be involved in gene silencing at centromeric regions in mice, because over-dosage of HP-1b by use of a transgene enhanced Role of Runx proteins in gene silencing I Taniuchi and DR Littman the silencing effect in the peri-centromeric regions, and suppressed PEV (Festenstein et al., 1999) . Similarly, the HP-1b transgene enhanced CD4 silencing in CD8 þ T cells in mice harboring a mutation at site 3 in the CD4 silencer, while the level of CD4 de-repression in immature CD4 À
À DN thymocytes was not affected by the HP-1b transgene (Taniuchi et al., 2002b ). An involvement of HP-1 in CD4 silencing in mature T cells, but not in CD4 repression in DN thymocytes, is consistent with irreversible epigenetic silencing that occurs at the later stage of thymocyte development.
Thus, epigenetic silencing is established at the CD4 locus by the CD4 silencer in lineage-restricted cells at a specific developmental stage. The CD4 silencer is currently the only discretely defined epigenetic silencer element identified in higher vertebrates, and provides a unique opportunity to study how specific loci are silenced during developmental processes.
Runx family proteins as binding factors to the CD4 silencer
Fine mapping analysis in transfection assays revealed that the minimal functional sequence of site 2 ( 232 GAC-CACA 238 ) in the silencer core was identical to a consensus Runx-binding motif (Figure 1a ) (Taniuchi et al., 2002a) . In addition, a search for functional sites in a 5 0 flanking region shown to be important in transgenic assays identified another Runx-binding motif (site 2 0 , 81 AACCACA 87 ) (Figure 1a ). Both Runx-binding motifs were required for full CD4 silencer activity, as the targeted mutation of either site resulted in variegated CD4 de-repression in mature CD8 þ T cells. However, mutation of both Runx motifs resulted in full CD4 derepression in all mature CD8-lineage T cells (Taniuchi et al., 2002a) . Interestingly, in immature DN thymocytes from mice harboring mutations of both consensus Runx sites, there was uniform de-repression of CD4, but the level of CD4 de-repression was lower than that upon deletion of the entire CD4 silencer (Taniuchi et al., 2002a) . Therefore, it is likely that the function of Runx sites is partially compensated by other functional sites in immature DN thymocytes. However, when epigenetic CD4 gene silencing is established, Runx sites, and presumably binding of Runx proteins to the sites, are indispensable for the activity of the CD4 silencer.
Transcripts of all the three Runx genes (Runx1, Runx2 and Runx3) were detected in all thymocyte subsets with higher amounts of Runx1 and Runx2 transcripts in the DN subset and relatively higher amounts of Runx3 transcript in CD8 þ SP thymocytes than in CD4 þ SP thymocytes (Satake et al., 1995; Taniuchi et al., 2002a) . Genetic approaches revealed that two of these Runx family members play important roles in CD4 gene regulation (Taniuchi et al., 2002a) . Runx1 was shown to be required for CD4 repression in immature DN thymocytes, while Runx3 was shown to be required for establishment of epigenetic CD4 silencing in CD8 lineage T cells (Figure 1b) .
The function of Runx1 during T-lymphocyte development was analysed by using a mutant Runx1 allele (Runx1 f ), in which the exon encoding the C-terminal part of the runt domain in Runx1 was flanked with two loxP sites. Crossing of Runx1 f mice to the Lck-Cre transgenic strain inactivates the Runx1 gene in prothymocytes. In the mutant mice that lack Runx1 at the DN immature thymocyte stage, CD4 was de-repressed to a level similar to that observed when both Runxbinding sites were mutated (Taniuchi et al., 2002a) . In contrast to these analyses of Runx1 function, CD4 repression in immature DN thymocytes was not affected in the absence of Runx3. However, reconstitution of Tlymphocyte development in a T cell-deficient host with Runx3-deficient progenitors revealed that the Runx3 deficiency resulted in variegated de-repression of CD4 in mature CD8-lineage cells (Taniuchi et al., 2002a) . In comparison, there was no apparent CD4 de-repression in mature CD8 lineage cells upon Runx1 inactivation during thymocyte differentiation (Taniuchi et al., 2002a) . The variegation in CD4 de-repression is likely due to a partial compensatory function of Runx1, since full de-repression of CD4 in CD8 lineage T cells was reported recently in mice with the compound Runx1 (Woolf et al., 2003) . Consistent with these findings, full CD4 de-repression was observed upon mutation of the double Runxbinding sites in the CD4 silencer. Therefore, Runx1 is likely to be involved in the initiation of epigenetic CD4 silencing in a manner similar to Runx3. Since Runx3 appears to be expressed primarily in medullary CD8 þ SP thymocytes, while Runx1 is expressed at the highest levels in immature cortical thymocytes, the loss of Runx3 might be predicted to more readily result in CD4 de-repression. However, it is also possible that either Runx1 or Runx3 has a unique function for active repression in DN thymocytes and for epigenetic silencing in CD8 þ SP mature thymocytes, respectively.
Mechanisms of CD4 repression by Runx proteins
How do Runx proteins repress target genes? Runx proteins are known to recruit HDACs by interacting with several co-repressor molecules, including Groucho/ TLE, which binds to the highly conserved C-terminal sequence VWRPY, as well as Sin3A (Levanon et al., 1998; Lutterbach et al., 2000; Wheeler et al., 2000) . It is therefore possible that recruitment of HDACs by the Runx complex contributes not only to active repression in DN thymocytes but also to epigenetic silencing in CD8 SP thymocytes. However, there is likely to be an additional recruitment of the epigenetic machinery that is required to complete heterochromatinization, as simple treatment of mature CD8 þ SP T cells with TSA, an HDAC inhibitor, could not initiate reexpression of CD4 (Zou et al., 2001) . As histone H3 methylated at lysine 9 is also thought to be a platform for HP-1 recruitment in mammals (Jenuwein & Allis, 2001; Nielsen et al., 2001) , genetic association of HP-1 with the silenced CD4 locus suggests that a HMT for lysine 9 of histone H3 might be involved in CD4 silencing. It is noteworthy that Runx1 was recently shown to associate in vitro with SUV39, a major mammalian HMT for methylation at lysine 9 of histone H3 (Chakraborty et al., 2003) .
Genetic approaches have revealed a role for the BAF complex, a mammalian counterpart of the yeast chromatin-remodeling complex, SWI/SNF, in CD4 gene regulation. Haploinsufficiency of Brg1 (the ATPase subunit) compounded with expression of a dominant negative form of BAF57 (a DNA-binding subunit containing an HMG box) resulted in partial CD4 derepression in immature DN thymocytes (Chi et al., 2002) . CD4 de-repression caused by impaired BAF function was enhanced in mice harboring a mutation at site 1 within the CD4 silencer. A chromatin immunoprecipitation assay (ChIP assay) indicated an association of the BAF complex with the CD4 silencer. These data suggest that the protein complex that interacts with the CD4 silencer in DN thymocytes contains both Runx1 and BAF molecules (Figure 1b) . Interestingly, in addition to the CD4 de-repression in DN thymocytes, inefficient (or variegated) CD8 expression was observed when the function of either Runx1 or the BAF complex was compromised. Similar variegated CD8 expression was also observed in mutant mouse strains with compound mutations in enhancers at the CD8 locus Garefalaki et al., 2002) . The similar phenotypes in these mutant mice suggest a functional association of Runx1 with the BAF chromatin-remodeling complex on CD8 enhancers, although biochemical evidence will be necessary to prove this. It is noteworthy that both Runx and the BAF chromatinremodeling complex appear to function reciprocally at distinct loci in the same cells: repression at the CD4 locus and activation at the CD8 locus. Therefore, Runx proteins function, in part, by recruiting the BAF chromatin-remodeling complex to direct either repression or activation of target genes.
As the CD4 silencer is not required for the maintenance of CD4 silencing, temporal binding of Runx to the CD4 silencer at a specific developmental stage is likely to be sufficient for shutting off the CD4 gene permanently. This does not imply that the Runx proteins are not required for the maintenance of CD4 silencing. It is possible that Runx proteins function, independently from the silencer, to maintain the silent status of CD4, similarly to HP-1 that is assembled at the silent loci by epigenetic mechanisms. Further genetic approaches for conditional inactivation of Runx genes in mature CD8 þ SP T cells will be necessary to clarify this issue.
Gene silencing by Runx proteins and carcinogenesis
It is unlikely that the CD4 gene is the only target locus that is epigenetically silenced by Runx proteins. If other target genes encode molecules that facilitate oncogenesis, loss of Runx function could result in carcinogenesis. It has been suggested that genomic alterations in stem cells are involved in the pathogenesis of acute myeloid leukemia (AML) (Lapidot et al., 1994) , a disease in which mutations of the RUNX1 gene are frequently observed (Miyoshi et al., 1991; Osato et al., 1999) . When loss of RUNX1 function in stem cells is caused by genomic alterations, such as translocations, the mark for Runx dysfunction persists in leukemic cells. However, it is possible that a temporal dysfunction of RUNX1 caused by a mechanism unrelated to genomic alterations of the RUNX1 gene would result in persistent activation of target oncogenes, in the absence of a scar left at the RUNX1 locus. Interestingly, temporal inactivation of Myc was shown to result in the sustained loss of the neoplastic phenotype (Jain et al., 2002) . It is therefore worthwhile to search for differences in chromatin structures at putative target loci of RUNX1 in leukemia patients bearing no mutation in the RUNX1 genes.
Studies of CD4 silencing have revealed novel activities of the Runx proteins in repressing target gene expression. Variegated CD8 expression upon Runx1 inactivation suggests that it is also possible that Runx functions epigenetically in gene activation. Further studies to understand the epigenetic mechanisms through which Runx proteins regulate target genes will provide new insights into the molecular mechanisms of how Runx dysfunction promotes carcinogenesis.
